Juha R.
- Country
- Finland
- Department
- Turku University Hospital
Research Overview
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
- Phase 3 Randomized Trial of Bortezomib, Lenalidomide, Dexamethasone, and Ciltacabtagene Autoleucel in Newly Diagnosed Multiple Myeloma Without Planned Stem Cell Transplant
- Phase II Randomized Study of MB-CART2019.1 Versus Standard Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for High-Dose Chemotherapy
Data & Insights
Has run more than one trial at 180 of 301 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating various blood cancers, with particular emphasis on multiple myeloma and chronic lymphocytic leukemia (CLL). Their research encompasses innovative therapeutic approaches for both newly diagnosed and treatment-naive patients.
- Multiple Myeloma Management
- Chronic Lymphocytic Leukemia Treatment
- Small Lymphocytic Lymphoma Therapy
Their clinical focus includes developing treatment strategies for patients who are not candidates for stem cell transplantation.
Novel Therapeutic Combinations
The investigator explores innovative drug combinations including venetoclax-based regimens and targeted therapies. Their work involves evaluating fixed-duration treatments against continuous therapy approaches.
- Combination Immunotherapy
- Targeted Molecular Treatments
- Duration-Optimized Protocols
Special attention is given to developing personalized treatment durations based on minimal residual disease monitoring.
Treatment Optimization
The investigator focuses on comparative effectiveness research in blood cancers, evaluating various therapeutic approaches to determine optimal treatment strategies.
- Treatment Duration Assessment
- Disease Progression Monitoring
- Therapeutic Response Evaluation
Their research emphasizes measuring progression-free survival across different treatment modalities.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.